We recently published 10 Stocks Lead Wall Street Downward Spiral. Zoetis Inc. (NYSE:ZTS) is one of the worst-performing stocks on Tuesday. Zoetis fell to a new 52-week low on Tuesday, as investor sentiment was dampened by a lower revenue growth outlook for full-year 2025. In intra-day trading, Zoetis Inc. (NYSE:ZTS) dropped to its lowest price of $122.03 before trimming gains to end the day just down by 13.78 percent at $124.46 apiece, after revenue guidance for full-year 2025 was reduced to a range of $ ...

We recently published 10 Stocks Lead Wall Street Downward Spiral. Navitas Semiconductor Corp. (NASDAQ:NVTS) is one of the worst-performing stocks on Tuesday. Navitas fell for a second day on Tuesday, shedding 14.61 percent to close at $10.46 apiece after a dismal earnings performance in the third quarter of the year. In a statement, Navitas Semiconductor Corp. (NASDAQ:NVTS) said it widened its net loss by 2.7 percent to $19.2 million from $18.7 million in the same period last year, on the back of lower r ...

We recently published 10 Stocks Lead Wall Street Downward Spiral. Norwegian Cruise Line Holdings Ltd. (NYSE:NCLH) is one of the worst-performing stocks on Tuesday. Norwegian Cruise fell by 15.28 percent on Tuesday to close at $18.79 apiece as investors soured on a mixed earnings result in the third quarter of the year. In an updated report, Norwegian Cruise Line Holdings Ltd. (NYSE:NCLH) said net income declined by 11.77 percent to $419 million from $474.9 million in the same period last year, amid highe ...

(Bloomberg) — The trade was simple — and worked until it didn’t. Wrap crypto in a stock ticker. Call it innovation. Ride the wave. This week, with the crypto complex buckling alongside a tech-stock selloff, that wave is crashing. And some of its biggest promoters — including President Donald Trump ally David Bailey, Ethereum bull Tom Lee and Bitcoin evangelist Michael Saylor — must now deal with the fallout. Bitcoin’s slide below $100,000 for the first time since June has ratcheted up pressure on shares ...

The US government is investigating JPMorgan Chase over an alleged “debanking” scandal after President Trump claimed the nation’s biggest bank was rejecting customers with conservative political ties. In a quarterly filing on Wednesday, JPMorgan Chase revealed it is “responding to requests from government authorities and other external parties regarding, among other things, the firm’s policies and processes and the provision of services to customers and potential customers.”JPMorgan claimed the probe is a re ...

EnglishItalianoEspañolPortuguêsDeutschالعربيةFrançaisImportant DisclaimersThe content provided on the website includes general news and publications, our personal analysis and opinions, and contents provided by third parties, which are intended for educational and research purposes only. It does not constitute, and should not be read as, any recommendation or advice to take any action whatsoever, including to make any investment or buy any product. When making any financial decision, you should perform your ...

芯片行业动态 - 芯片股遭遇大幅抛售，导致相关指数中的芯片股市值蒸发约5000亿美元 [1] - AMD第三季度业绩超预期且上调第四季度营收指引，但股价仍下跌，因华尔街对其已有过高期望 [2][3][7][8] - AMD与OpenAI和Oracle达成重大合作，但相关收入尚未入账，其下一代GPU的贡献将在未来体现 [3][9] - 超微公司股价下跌约8%，因业绩未达预期，且公司此前已下调季度指引 [10][11] - 超微公司生产采用英伟达芯片的服务器机架，并预计随着产品设计变更，未来收入将增长 [11][12] 加密货币市场 - 比特币价格跌破10万美元/枚，为自6月以来首次，较一个月前创下的历史高点下跌超过20% [2][22] - 比特币抛售压力部分来自“巨鲸”抛售，据10x Research数据，过去一个月长期持有者售出40万枚比特币 [23] - Compass Point指出，自6月30日起，长期持有者的净出售量已超过100万枚比特币 [24] - 分析师指出95,000美元附近可能形成支撑位，但缺乏近期催化剂，而政府重启、资金流入标普500指数及相关立法可能成为上行催化剂 [27][28][29] - 10月份比特币表现不佳，为自2018年以来首次，历史数据显示其在表现不佳的10月后，11月可能下跌37% [25] 消费行业与消费者趋势 - 麦当劳美国同店销售额连续第二个季度增长，主要得益于自2016年首次回归的3.99美元零食卷以及5美元和8美元价位的超值套餐 [14][15] - 麦当劳CEO指出第三季度低收入消费者支出下降近两位数，而高收入消费者支出增长近两位数，预计这种压力将持续至2026年 [16][17] - Cava同店销售额增长约1.9%，但远低于去年水平，公司已将全年同店销售额增长指引从6%-8%下调至3%-4% [19][20] - Cava指出25至35岁的年轻消费者面临学生贷款偿还、消费者情绪、通胀、医疗和住房成本压力，导致其消费能力减弱 [21][22] 科技公司业绩与动向 - Pinterest股价下跌，因其提供的营收展望弱于预期，且Rosenblatt将其股票评级从买入下调至中性，并提及对AI的担忧 [35] - Pinterest近期推出了AI驱动的视觉购物助手Pinterest Assistant [35] - IBM计划本季度裁员数千人，公司正将业务重点转向高增长的软件和服务，截至2024年底员工数约为27万人 [34] - 尽管科技股遭抛售，但约三分之二的标普500成分公司已公布财报，显示底部盈利实现两位数增长 [40] 制药行业竞争 - 诺和诺德第四次下调其肥胖和糖尿病药物的增长预期，并报告第三季度盈利令人失望，面临来自礼来的激烈竞争 [33] - 诺和诺德与辉瑞就肥胖症初创公司Mitsara展开竞购战，以寻求增长动力 [33] 宏观经济与市场观点 - ADP私人 payrolls报告显示上月美国经济增加4.2万个就业岗位，9月份数据从最初报告的减少3.2万个修正为减少2.9万个 [4] - 市场策略师认为当前回调是正常的，市场基本面依然稳固，科技公司及其他公司盈利强劲，标普500指数成分公司实现两位数底部盈利增长 [39][40][41] - 市场存在集中度风险，标普500指数创下的36个纪录高点中，半数由6只股票驱动，但这些公司贡献了大部分盈利和利润，且盈利基于真实业务 [42][43][44] - 大型科技公司开始通过债务市场为资本支出融资，而非仅依赖现金流，其资产负债表此前未得到充分利用，需警惕公司与资金提供方过度交织带来的“太大而不能倒”风险 [45][46][47]

Wall Street excels at creating catch phrases. The latest one is the "debasement trade. ...

Accessibility StatementSkip Navigation Paige Bueckers, Bryson DeChambeau, CeeDee Lamb and Draymond Green come face-to-face with Santa to secure their spot on this year's nice roster PITTSBURGH, Nov. 5, 2025 /PRNewswire/ -- This holiday season, DICK'S Sporting Goods (NYSE: DKS) is partnering with some of the biggest names in sports to launch Santa's Scouting Report, a campaign that puts a playful, sports-themed spin on the classic naughty or nice list. Santa's Scouting Report Santa's Scouting Report - Hero I ...

收购竞价战核心进程 - 辉瑞最初于9月同意以49亿美元收购Metsera，加上未来付款后总额可达73亿美元 [5] - 诺和诺德于上周四提出约60亿美元的竞争性收购要约，加上未来付款后总额可达90亿美元，触发辉瑞在四个工作日内重新谈判的期限 [6] - 截至本周二，Metsera认为诺和诺德最新提出的高达100亿美元的出价优于辉瑞修订后的约81亿美元报价 [9] - 根据原始协议条款，辉瑞有两个工作日的时间谈判调整其提案，之后若Metsera董事会仍认为诺和诺德方案更优，则有权终止与辉瑞的合并协议 [10] 法律纠纷与公司回应 - 辉瑞于上周五提起首次诉讼，旨在阻止Metsera终止与其的现有合并协议 [7] - 辉瑞于本周一提起第二起诉讼，指控诺和诺德的竞购行为是反竞争的，并指控Metsera控股股东与诺和诺德合谋 [16] - 辉瑞的首起诉讼主张诺和诺德的要约因重大监管风险而无法构成“更优提案” [17] - Metsera称辉瑞的诉讼论点为“无稽之谈”，并将在法庭上进行回应 [7] - 诺和诺德回应称辉瑞关于其意图抑制创新的指控是虚假且毫无根据的 [17] - 辉瑞首席财务官表示公司将利用所有合法权利，并继续通过多种途径主张其权利 [19] 收购目标Metsera的价值分析 - Metsera成立于2022年，拥有通过许可和收购获得的口服和注射疗法产品线，包括一种GLP-1药物和一种胰淀素治疗药物 [11] - 其正在开发的药物可实现每月一次给药，频率低于现有的每周注射剂 [11] - 分析师指出，尚不清楚Metsera的GLP-1或胰淀素药物与诺和诺德自有药物相比是否具有差异化，其每月一次给药方法的可行性也尚未得到证实 [14] - 收购Metsera对辉瑞而言是进入利润丰厚肥胖症市场的关键机会，因其自身减肥药候选药物在过去两年因安全问题连续受挫 [12] - 诺和诺德虽开创了减肥药市场，但过去一年市场份额被礼来夺取，且现有产品线未能给投资者留下深刻印象，面临来自安进、罗氏等新竞争者的压力 [13] 行业与市场背景 - 诺和诺德是高效GLP-1药物（如Ozempic和Wegovy）的市场领导者，但正急于夺回市场领先地位 [13] - 分析师认为，诺和诺德竞购Metsera的目的既为自身发展，也为防止该生物技术公司的药物落入辉瑞或其他制药商之手 [15] - 根据健康政策研究组织KFF数据，保险公司已将明年保费平均提高26% [22]